The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?
Authors
Keywords
-
Journal
Journal of Diabetes Research
Volume 2015, Issue -, Pages 1-28
Publisher
Hindawi Limited
Online
2015-05-18
DOI
10.1155/2015/806979
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
- (2015) Yuichi Makino et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes
- (2015) Takeshi Nishimura et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dipeptidyl peptidase-IV inhibition prevents blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats
- (2014) Andreia Gonçalves et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
- (2014) Christian Ott et al. Cardiovascular Diabetology
- Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
- (2014) Liam M. McCormick et al. Circulation-Cardiovascular Imaging
- Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
- (2014) Peter Vavrinec et al. Current Vascular Pharmacology
- The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
- (2014) Angelo Avogaro et al. DIABETES CARE
- The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits
- (2014) R. E. J. Ryder DIABETIC MEDICINE
- Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2014) Greg L. Plosker DRUGS
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- The potential for renoprotection with incretin-based drugs
- (2014) Tetsuhiro Tanaka et al. KIDNEY INTERNATIONAL
- Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
- (2014) Catarina Marques et al. MEDIATORS OF INFLAMMATION
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat
- (2014) Ravi Nistala et al. Obesity
- Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors
- (2014) Atsuo Tahara et al. Pharmacological Reports
- Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms
- (2014) Belén Picatoste et al. PLoS One
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
- (2014) L. Li et al. BMJ-British Medical Journal
- Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate 西格列汀通过降低2型糖尿病患者的血压以及估算的肾小球滤过率来减少尿白蛋白/肌酐的比值
- (2014) Isao Kawasaki et al. Journal of Diabetes
- The role of incretin-based therapies in prediabetes: A review
- (2014) Hala Ahmadieh et al. Primary Care Diabetes
- Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study
- (2013) Shigemasa Tani et al. American Journal of Cardiovascular Drugs
- Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes
- (2013) Ryo Kodera et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
- (2013) Anthony H. Barnett et al. CLINICAL DRUG INVESTIGATION
- The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
- (2013) Dara L. Eckerle Mize et al. Current Diabetes Reports
- Physiology and pathophysiology of incretins in the kidney
- (2013) Karoline von Websky et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Gut hormones as therapeutic agents in treatment of diabetes and obesity
- (2013) Tricia Tan et al. CURRENT OPINION IN PHARMACOLOGY
- Incretin actions beyond the pancreas: lessons from knockout mice
- (2013) Daisuke Yabe et al. CURRENT OPINION IN PHARMACOLOGY
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
- (2013) D. Wang et al. DIABETES
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study
- (2013) H. Yki-Jarvinen et al. DIABETES CARE
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1^|^alpha; in type 2 diabetic patients with incipient nephropathy
- (2013) Hiroki Fujita et al. ENDOCRINE JOURNAL
- Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats
- (2013) Annayya R. Aroor et al. ENDOCRINOLOGY
- Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: Role of GLP-1 and GLP-1 receptor
- (2013) Dalia M. Abd El Motteleb et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
- (2013) Carolyn F Deacon et al. EXPERT OPINION ON PHARMACOTHERAPY
- The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
- (2013) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial Effects of Vildagliptin on Retinal Injury in Obese Type 2 Diabetic Rats
- (2013) Satoshi Maeda et al. OPHTHALMIC RESEARCH
- Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
- (2013) Hiroko Mori et al. Journal of Diabetes Investigation
- GLP-1 based agents and acute pancreatitis
- (2013) E. A. M. Gale BMJ-British Medical Journal
- Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes
- (2013) Karen Pillay et al. Biomed Research International
- Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?
- (2013) Belinda Gier et al. JAMA Internal Medicine
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- The future role of gut hormones in the treatment of obesity
- (2013) Rachel C. Troke et al. Therapeutic Advances in Chronic Disease
- Update on incretin hormones
- (2012) Liza K. Phillips et al. Annals of the New York Academy of Sciences
- The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells
- (2012) Aya Shiraki et al. ATHEROSCLEROSIS
- Incretin-based Therapies for Type 2 Diabetes
- (2012) Christopher H.S. McIntosh Canadian Journal of Diabetes
- DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes
- (2012) Kim Alexander Connelly et al. Cardiovascular Therapeutics
- Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
- (2012) Ulrike Graefe-Mody et al. CLINICAL PHARMACOKINETICS
- Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
- (2012) Joshua J. Neumiller et al. CLINICAL THERAPEUTICS
- Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
- (2012) Anthony H. Barnett et al. CURRENT MEDICAL RESEARCH AND OPINION
- Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model
- (2012) Belinda Gier et al. DIABETES
- GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2-Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States
- (2012) G. J. Hein et al. DIABETES
- Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes
- (2012) J. Vora et al. DIABETES & METABOLISM
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
- (2012) G. P. Fadini et al. DIABETES CARE
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
- (2012) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
- (2012) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study
- (2012) E. S. Hong et al. DIABETES OBESITY & METABOLISM
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
- (2012) M. Wenten et al. DIABETIC MEDICINE
- Saxagliptin
- (2012) Lily P.H. Yang DRUGS
- Linagliptin
- (2012) Emma D. Deeks DRUGS
- Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
- (2012) Vivian Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
- (2012) Pablo Aschner et al. LANCET
- Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
- (2012) Takashi Kadowaki et al. Journal of Diabetes Investigation
- The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*†
- (2012) Wenying YANG et al. Journal of Diabetes
- Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*
- (2012) Adrian S. DOBS et al. Journal of Diabetes
- The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database
- (2011) E. Raschi et al. ACTA DIABETOLOGICA
- Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
- (2011) Nir Barzilai et al. CURRENT MEDICAL RESEARCH AND OPINION
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
- (2011) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
- (2011) L. Olansky et al. DIABETES OBESITY & METABOLISM
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
- (2011) J. Wainstein et al. DIABETES OBESITY & METABOLISM
- A cohort study of acute pancreatitis in relation to exenatide use
- (2011) D. D. Dore et al. DIABETES OBESITY & METABOLISM
- The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
- (2011) C. Reasner et al. DIABETES OBESITY & METABOLISM
- Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model
- (2011) A. Gonçalves et al. DIABETES OBESITY & METABOLISM
- Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus
- (2011) DIABETES RESEARCH AND CLINICAL PRACTICE
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
- (2011) Matteo Monami et al. Experimental Diabetes Research
- Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
- (2011) Cristina Mega et al. Experimental Diabetes Research
- Sitagliptin: a review
- (2011) Sreevidya Subbarayan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience
- (2011) J. H. Martin et al. INTERNAL MEDICINE JOURNAL
- Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes
- (2011) A. Pérez-Monteverde et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
- (2011) K. H. Yoon et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation
- (2011) Daisuke Yabe et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
- (2011) Susumu Ogawa et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
- (2011) Zubair Shah et al. VASCULAR PHARMACOLOGY
- Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
- (2011) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
- Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8)
- (2010) Melissa R. Pitman et al. BIOLOGICAL CHEMISTRY
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
- (2010) K. J. Hare et al. DIABETES
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
- (2010) D. Williams-Herman et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study
- (2010) Y. Iwamoto et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
- (2010) Y. Iwamoto et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
- (2010) R. Arechavaleta et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
- (2010) C. Filozof et al. DIABETIC MEDICINE
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- Vildagliptin
- (2010) Gillian M. Keating DRUGS
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
- (2010) S. S. Engel et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
- (2010) Liliana Ferreira et al. MEDIATORS OF INFLAMMATION
- GIP and GLP-1, the two incretin hormones: Similarities and differences
- (2010) Yutaka Seino et al. Journal of Diabetes Investigation
- Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
- (2009) Shrikanth H. Havale et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
- (2009) Debora Williams-Herman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin
- (2009) A. V. Matveyenko et al. DIABETES
- Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes
- (2009) C. W. Chia et al. DIABETES
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
- (2009) G. Bolli et al. DIABETES OBESITY & METABOLISM
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- (2009) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
- (2009) P. Aschner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
- (2009) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus
- (2009) Masatoshi Kikuchi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
- (2009) J. S. Nachnani et al. DIABETOLOGIA
- Minireview: Finding the Sweet Spot: PeripheralVersusCentral Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis
- (2009) Diana L. Williams ENDOCRINOLOGY
- Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice
- (2009) Michele D’Amico et al. EXPERIMENTAL GERONTOLOGY
- Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice
- (2009) Adriano Maida et al. GASTROENTEROLOGY
- Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes
- (2009) J. E. Foley et al. HORMONE AND METABOLIC RESEARCH
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states
- (2009) Bernardo Nuche-Berenguer et al. REGULATORY PEPTIDES
- Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice
- (2008) Frank Isken et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Incretin and islet hormonal responses to fat and protein ingestion in healthy men
- (2008) Richard D. Carr et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice
- (2008) Rei Naitoh et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice
- (2008) S.-J. Kim et al. DIABETES
- Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease
- (2008) B. Martin et al. DIABETES
- Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
- (2008) R. Scott et al. DIABETES OBESITY & METABOLISM
- Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*
- (2008) A. J. Garber et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
- (2008) Kenji Nonaka et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
- (2008) Viswanathan Mohan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
- (2008) C. Pan et al. DIABETIC MEDICINE
- Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
- (2008) D. M. Nathan et al. DIABETOLOGIA
- Protection of exendin-4 analogue in early experimental diabetic retinopathy
- (2008) Yu Zhang et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet
- (2008) Matthew C. Althage et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- KATPChannel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes
- (2008) Kasper Aaboe et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
- (2008) L R Ranganath JOURNAL OF CLINICAL PATHOLOGY
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The incretin system and its role in type 2 diabetes mellitus
- (2008) J HOLST et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Intracerebroventricular infusion of neuropeptide Y increases glucose dependent-insulinotropic peptide secretion in the fasting conscious dog
- (2008) Maria P. Yavropoulou et al. PEPTIDES
- The entero-insular axis: implications for human metabolism
- (2007) Lakshminarayan R. Ranganath CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects
- (2007) Aine M. McKillop et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
- (2007) Chizumi Yamada et al. ENDOCRINOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started